https://www.selleckchem.com/pr....oducts/acetylcystein
We aimed to assess whether the safety outcomes exerted by sodium-glucose cotransporter 2 (SGLT2) inhibitors were associated with different renal function at baseline. We searched randomized controlled trials comparing SGLT2 inhibitors with placebo in participants simultaneously involving the entire range of estimated glomerular filtration rate (eGFR) levels at baseline in one study. According to eGFR, we divided the population into two subgroups with eGFR 60ml/min/1.73m and eGFR≥60ml/min/1.73m . Data from the CANVAS program,
Like
Comment
Share
